The prophylactic treatment of chronic daily headache

Headache

Volumn 46, Issue 10, 2006, Pages 1552-1564

  Mathew, Ninan T ^a  

^a Houston Headache Clinic   (United States)

Author keywords

Active comparator controlled trials; Botulinum toxin type A; Chronic daily headache; Double blind; Placebo controlled trials; Prophylaxis

Indexed keywords

AMITRIPTYLINE; BOTULINUM TOXIN A; FLUOXETINE; GABAPENTIN; PLACEBO; TIZANIDINE; TOPIRAMATE;

ASTHENIA; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DAILY HEADACHE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; DISABILITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSARTHRIA; DYSPHAGIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARTBURN; HEMICRANIA CONTINUA; HUMAN; HYPESTHESIA; INJECTION SITE PAIN; MIGRAINE; MUSCLE HYPERTONIA; MUSCLE WEAKNESS; MYALGIA; NECK PAIN; POPULATION; PRIORITY JOURNAL; PROPHYLAXIS; PTOSIS; QUALITY OF LIFE; RESTLESSNESS; REVIEW; RIGIDITY; SHOULDER PAIN; SIDE EFFECT; SKIN TIGHTNESS; SLEEP DISORDER; SOMNOLENCE; STOMACH PAIN; TENSION HEADACHE; TREATMENT DURATION; TREMOR; VOMITING; WEIGHT GAIN; XEROSTOMIA;

CHRONIC DISEASE; HEADACHE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 33750856838     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2006.00621.x     Document Type: Review

References (46)

1. Castillo J, Munoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache. 1999;39:190-196.
2. Silberstein SD, Lipton RB. Chronic daily headache. Curr Opin Neurol. 2000;13:277-283.
3. Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache in Chinese elderly: Prevalence, risk factors, and biannual follow-up. Neurology. 2000;54:314-319.
4. Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep. 2001;5:529-536.
5. Silberstein SD. Transformed and chronic migraine. In:Goadsby P, Silberstein, S, Dodick D, eds. Chronic Daily Headache for Clinicians. Hamilton, Ontario: BC Decker, Inc.; 2005:21-56.
6. Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache. 1987;27:102-106.
7. Mathew NT. Chronic refractory headache. Neurology. 1993;43(suppl 3):S26-S33.
8. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: Field trial of revised IHS criteria. Neurology. 1996;47:871-875.
9. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: A comparison of chronic migraine with episodic migraine. Headache. 2003;43:336-342.
10. Duru G, Auray JP, Gaudin AF, et al. Impact of headache on quality of life in a general population survey in France (GRIM2000 Study). Headache. 2004;44:571-580.
11. Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache. 2001;41:573-578.
12. Fusco BM, Colantoni O, Giacovazzo M. Alteration of central excitation circuits in chronic headache and analgesic misuse. Headache. 1997;37:486-491.
13. Scher AI, Stewart WF, Lipton RB. Epidemiology of chronic daily headache. In: Goadsby P, Silberstein S, Dodick D, eds. Chronic Daily Headache for Clinicians. Hamilton, Ontario:BCDecker, Inc.; 2005:3-11.
14. Silberstein SD, Goadsby PJ. Migraine: Preventive treatment. Cephalalgia. 2002;22:491-512.
15. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med. 2002;346:257-270.
16. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003;23:820-824.
17. Spira PJ, Beran RG, Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: A randomized, placebo-controlled study. Neurology. 2003;61:1753-1759.
18. Saper JR, Lake AE 3rd, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: A double-blind, placebo-controlled, multicenter outcome study. Headache. 2002;42:470-482.
19. Saper JR, Silberstein SD, Lake AE 3rd, Winters ME. Double-blind trial of fluoxetine: Chronic daily headache and migraine. Headache. 1994;34:497-502.
20. Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: A double-blind study. Headache. 2002;42:510-514.
21. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, for the BOTOX CDH Study Group. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Headache. 2005;45:293-307.
22. Silberstein SD, Stark SR, Lucas SM, Christie SM, DeGryse RE, Turkel CC. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005;80:1126-1137.
23. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack: Clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000;123(Pt 8):1703-1709.
24. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2001;89:107-110.
25. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003;43(suppl 1):S9-S15.
26. Bone M, Critchley P, Buggy DJ. Gabapentin in postamputation phantom limb pain: A randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med. 2002;27:481-486.
27. Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2005;6:108-113.
28. Sills GJ. Not another gabapentin mechanism! Epilepsy Curr. 2005;5:75-77.
29. Coward DM. Tizanidine: Neuropharmacology and mechanism of action. Neurology. 1994;44(11 suppl 9):S6-S10.
30. Adly C, Straumanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache. 1992;32:101-104.
31. Saper JR, Silberstein SD, Gordon CD, Hamel RL. Handbook of Headache Management; A Practical Guide to Diagnosis and Treatment of Head, Neck, and Facial Pain. Baltimore, MD: Williams & Wilkins; 1993;58-67.
32. Brandes JL, Saper JR, Diamond M, et al. MIGR-002 Study Group. Topiramate for migraine prevention: A randomized controlled trial. JAMA. 2004;291:965-973.
33. Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol. 2004;61:490-495.
34. Dolly O. Synaptic transmission: Inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43(suppl 1):S16-S24.
35. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125-133.
36. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache. 2004;44:35-43.
37. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD; BOTOX CDH Study Group. Botulinum toxin type A for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-controlled study. Headache. 2005;45:315-324.
38. Tfelt-Hansen P, Block G, Dahlof C, et al, for the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia. 2000;20:765-786.
39. Linde M, May A, Limmroth V, Dahlof C, Headache Masters Programme.Ethical aspects of placebo in migraine research. Cephalalgia. 2003;23:491-495.
40. Silberstein S, Mathew N, Saper J, Jenkins S, for the BOTOX® Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache. 2000;40:445-450.
41. Barrientos N, Chana P. Botulinum toxin type A in prophylactic treatment of migraine headaches: A preliminary study. J Headache Pain. 2003;4:146-151.
42. Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine - A randomized, double-blind, placebo-controlled study. Cephalalgia. 2004;24:838-843.
43. Malick A, Burstein R. Peripheral and central sensitization during migraine. Funct Neurol. 2000;15(suppl 3):28-35.
44. Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology. 2004;63:848-852.
45. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: Concerns about side effects may delay treatment. Headache. 2003;43:36-43.
46. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre - clinical characteristics and treatment outcomes. Cephalalgia. 2004;24:483-490.